As the Asian markets navigate a period of volatility driven by technology sector fluctuations and geopolitical tensions, investors are increasingly focused on identifying resilient opportunities within the region. In this context, growth companies with high insider ownership can offer potential stability and alignment of interests, making them appealing in uncertain times.
Top 10 Growth Companies With High Insider Ownership In Asia
| Name | Insider Ownership | Earnings Growth |
| Zhejiang Taotao Vehicles (SZSE:301345) | 27.9% | 31.5% |
| Seojin SystemLtd (KOSDAQ:A178320) | 22% | 110.6% |
| SEERS (KOSDAQ:A458870) | 33.2% | 41.5% |
| Meiko Electronics (TSE:6787) | 19.2% | 28.0% |
| L&C BIOLTD (KOSDAQ:A290650) | 24% | 148.5% |
| Jiangxi Fushine Pharmaceutical (SZSE:300497) | 21.1% | 55.9% |
| HUMAN MADE (TSE:456A) | 23.9% | 23.4% |
| Guangzhou Tinci Materials Technology (SZSE:002709) | 38.4% | 28.9% |
| Great Microwave Technology (SHSE:688270) | 29.5% | 85.5% |
| Fulin Precision (SZSE:300432) | 10.4% | 60.7% |
Here we highlight a subset of our preferred stocks from the screener.
ALTEOGEN (KOSDAQ:A196170)
Simply Wall St Growth Rating: ★★★★★★
Overview: ALTEOGEN Inc. is a biotechnology company specializing in the development of long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars, with a market cap of ₩16.42 trillion.
Operations: The company's revenue primarily comes from its biotechnology segment, totaling ₩203.76 million.
Insider Ownership: 25.4%
Earnings Growth Forecast: 44.3% p.a.
Alteogen's earnings are forecast to grow significantly at 44.3% per year, outpacing the KR market average. Its revenue is also expected to increase rapidly by 47.7% annually, supported by innovative advancements such as the subcutaneous formulation of antibody-drug conjugates using ALT-B4, which enhances drug absorption and safety profiles. Trading below its estimated fair value, Alteogen presents potential growth opportunities despite no recent insider trading activity reported over the past three months.
- Click here and access our complete growth analysis report to understand the dynamics of ALTEOGEN.
- Our comprehensive valuation report raises the possibility that ALTEOGEN is priced higher than what may be justified by its financials.
PharmaResearch (KOSDAQ:A214450)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: PharmaResearch Co., Ltd., along with its subsidiaries, is a biopharmaceutical company operating mainly in South Korea, with a market cap of ₩3.74 trillion.
Operations: The company generates revenue through its pharmaceuticals segment, amounting to ₩565.48 billion.
Insider Ownership: 35%
Earnings Growth Forecast: 21.3% p.a.
PharmaResearch's earnings are forecast to grow significantly at 21.25% annually, although this is slower than the KR market average of 31.9%. Revenue growth is expected at 19.6% per year, surpassing the KR market rate of 16%. The company trades at a good value, priced 60.4% below its estimated fair value, with a high forecasted return on equity of 26.3%. Recent presentations highlight ongoing engagement with investors and analysts without recent insider trading activity reported.
- Navigate through the intricacies of PharmaResearch with our comprehensive analyst estimates report here.
- According our valuation report, there's an indication that PharmaResearch's share price might be on the cheaper side.
Sigenergy Technology (SEHK:6656)
Simply Wall St Growth Rating: ★★★★★★
Overview: Sigenergy Technology Co., Ltd specializes in developing and manufacturing energy storage systems, inverters, and smart energy solutions for various applications, with a market cap of approximately HK$77.74 billion.
Operations: The company's revenue primarily comes from its Batteries / Battery Systems segment, which generated approximately CN¥9 billion.
Insider Ownership: 22%
Earnings Growth Forecast: 32.7% p.a.
Sigenergy Technology is positioned for robust growth, with earnings and revenue forecasted to grow significantly at 32.72% and 29.3% annually, respectively, outpacing the Hong Kong market averages. The company is trading at a substantial discount of 38.7% below its fair value estimate, indicating potential undervaluation. Recent product launches like the SigenMate 2700 Ultra highlight Sigenergy's innovation in AI-driven energy solutions across diverse markets, supported by a strong global distribution network without recent insider trading activity reported.
- Click to explore a detailed breakdown of our findings in Sigenergy Technology's earnings growth report.
- Our comprehensive valuation report raises the possibility that Sigenergy Technology is priced lower than what may be justified by its financials.
Next Steps
- Unlock our comprehensive list of 489 Fast Growing Asian Companies With High Insider Ownership by clicking here.
- Contemplating Other Strategies? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com